/
As of December 31, 2025, we manage and operate a diverse portfolio of four (4) wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors: Northstrive Biosciences Inc. ( Northstrive Biosciences ) is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. Our lead asset, EL-22, is leveraging …
The business is unprofitable at the operating level (-372.89% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$590K
Net Income (TTM)
-$11M
▼ -24.0% YoY
Op. Margin
-372.89%
ROIC
-26.38%
Cash Flow & Balance Sheet
FCF (FY)
-$6M
▼ -16.0% YoY
Op. Cash Flow (TTM)
-$8M
▼ -8.1% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$15M
Continue Research